Enzolytics Inc (OTCMKTS:ENZC) Is Back In Action: Now What?

On May 19 Enzolytics Inc (OTCMKTS:ENZC) was in focus after it provided a key update to its shareholders. The company announced in its update that the ownership of its patented technology was held in the name of The Zhabilov Trust exclusively and Diana Zhabilov served as the trustee of the entity.

Virogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science Review

The nature of the ownership was clear to see in the review of the records that had been filed with the United States Patent and Trademark Office. The company’s fully owned subsidiary unit Virogenetics remained the exclusive licensee for ITV-1 and also the exclusive licensee for the same in the United States and the rest of the IPF Immune countries.

Enzolytics categorically noted that any claim made by any other company was false. The company went on to note that it believed Nika Pharmaceuticals was in league with the accounts that had been posting lies and misinformation on social media platforms like Twitter. Enzolytics claimed that Nika was also making false claims on SEC filings and on its own website regarding the whole matter.

Enzolytics also announced that it was going to be featured in the June issue of Life Science Review Magazine as the most innovative monoclonal antibody company.